NEW YORK, Feb. 22, 2018 -- Guanidinoacetic acid (GAA) or Glycocyamine is the biochemical precursor of creatine, which is phosphorylated. It plays an important role as a high-energy carrier in the muscle. Glycocyamine is actually a metabolite of glycine in which the amino group has been converted into a guanidine. Guanidinoacetic acid can be used to increase muscle strength and to reduce muscle fatigue. And add guanidinoacetic acid into fodder can make lean pig’s body improve significantly. GAA might be considered as an innovative way to improve exercise performance. It has recently been suggested as a possible alternative to creatine to tackle brain creatine levels in experimental medicine. Due to upgraded bioavailability and convenient utilization of the compound, taking GAA orally might be beneficial for AGAT patients. But it has several drawbacks like brain methylation issues, neurotoxicity, and hyperhomocysteinemia.
From studies it has been observed that a combination of betaine and glycocyamine improves the symptoms of patients with chronic illness, including heart disease, without toxicity. Betaine provides methyl group to glycocyamine, via methionine, for the formation of creatine. Because of this, such treatment led to less fatigue, greater strength and endurance, and an improved sense of well-being. It is also useful for the patients with cardiac decompensation (arteriosclerosis or rheumatic disease) and congestive heart failure for improving cardiac function. It is also helpful in gained weight (improved nitrogen balance) and saw lessened symptoms of arthritis and asthma and increased libido. People suffering from hypertension experienced transient reduced blood pressure. It also increase of glucose tolerance in both diabetic and without diabetes subjects.
Free Sample Request: https://www.profsharemarketresearch.com/sample/guanidinoacetic-acid-market-report-sample/
Guanidinoacetic Acid Market: By Product Type
• Feed Grade
• Pharmaceutical Grade
Guanidinoacetic Acid Market: End Users/ Applications
• Fodder
• Medicine
Guanidinoacetic Acid Market: Regional Analysis
1.2.1 North America
• U.S.A
1.2.2 Europe
• Germany
• France
• Italy
• Spain
• UK
• Rest of Europe
1.2.3 Asia Pacific
• China
• Japan
• India
• South Korea
1.2.4 Latin America
• Brazil
1.2.5 Middle East and Africa
Guanidinoacetic Acid Market: Companies Covered
• Evonik (Germany)
• GENDONE (China)
• HebeiDaxiao (China)
• TianchengChempharm (China)
• Lubon Industry (China)
• Hubei Yuanhua (China)
• Jiangsu Yuanyang (China)
• Shijiazhuang Zexing (China)
Buy Reports: https://www.profsharemarketresearch.com/buy/guanidinoacetic-acid-market-report-buy-su/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295
www.profsharemarketresearch.com


Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
ADNOC Gas Targets Up to $4B Profit in 2026
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Shein Scales Back Vietnam Operations as US Trade Rules Shift
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



